← Leaderboards
Sripathi M Sureban
Coare Biotechnology, Inc.
$2,597,626
Attributed
$2,597,626
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2016–18$2M$1.5M$1M$500K$0
'16
'17
'18
Funding mix
By agency
NIH$2,597,626 · 3
By mechanism
R44$2,597,626 · 3
Top collaborators
No co-investigators on record.
Most similar at Coare Biotechnology, Inc.
Same institution · by research overlap
- Panayotis Pantazis$366,152
- Michael J Schlosser$449,950
Others in their field
Top investigators on “Success”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$298,740,071
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$277,058,716
- Lawrence Corey · Fred Hutchinson Cancer Center$274,406,165
- Barton F Haynes · Duke University$260,353,372
Research focus
SuccessTumorNeoplasm MetastasisSprague-Dawley RatsTissuesToxic EffectMesenchymalMouse ModelPhosphotransferasesSmall Business Innovation Research GrantSurvival RateTargeted TreatmentImmunogenicityCommercializationMalignant NeoplasmsClinical TrialsBaseDrug KineticsNonhuman PrimateNovel TherapeuticsEpithelialPreparationIn VivoTumorigenesis
Grant awards (4)
Pre-IND development of CBT-15 monoclonal antibody therapy against renal cell cancer$298,835
R44 · FY2018 · CA · contact PI
Development of a DCLK1 siRNA Nanoparticle as Targeted Therapy to Treat Pancreatic Cancer$298,791
R44 · FY2018 · CA · contact PI
Development of Monoclonal Antibodies to Treat Pancreatic Cancer$1,094,011
R44 · FY2017 · CA · contact PI
Development of Monoclonal Antibodies to Treat Pancreatic Cancer$905,989
R44 · FY2016 · CA · contact PI